For Mankind, this is a strategic investment in the field of treatment of cancer cachexia, amyotrophic lateral sclerosis, and other muscle-wasting disorders.
Morgan Stanley maintained an equal-weight rating on M&M Finance with a target price of Rs 300. Disbursements and collections remained strong in July. Collection efficiency in July was also marginally better.
Mankind Pharma’s branded prescription business grew 18 per cent YoY in Q4 , driven by core therapies of Anti-Infective, Respiratory and GI. Its Consumer Healthcare business grew 10 per cent YoY on account of higher rural penetration.